Drug Pricing by Country
List, net, and the reality between.
Country-by-country drug pricing intelligence — list, net, reference pricing chains and HTA dynamics — for launch and access teams.
"How should we price country-by-country to optimize global revenue?"
Country pricing isn’t about list price. It’s about net, reference-pricing cascades, payer placement and indication-based pricing — for every country in the launch sequence.
Country pricing is the most under-modeled launch decision. Net price, reference cascades and HTA timing — by country, in sequence — define realized global revenue.
What we’re seeing in the data.
Net price diverges sharply from list
Often 30–60% below.
EU reference-pricing cascades
NICE leads, others follow.
Indication-based pricing emerging
Same molecule, different prices.
How to think about it.
-
01
Pull list and net
IQVIA + claims.
-
02
Map reference chains
EU + global.
-
03
Score payer placement
Formulary and tier.
-
04
Optimize launch sequence
Geo prioritization.
What separates a good answer from a defensible one.
Triangulate.
Affects effective launch.
Affect adoption.
Where the signal comes from.
Common questions.
Why not just list price?
Net is often 30–60% below — strategy off list is structurally wrong.
Country sequence?
Country-specific reimbursement and reference rules drive optimal sequence.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist